T

Tabula

Develops ML-guided, programmable antimicrobials

Founding Machine Learning Scientist

Full-Time
No salary listed
Mid
San Francisco, CA, USA
In Person
AI & Machine LearningApplied Machine Learning

About the job

Requirements
  • Strong background in modern machine learning and deep learning.
  • Fluency in Python and PyTorch, plus comfort with the broader modern machine learning stack.
  • Ability to reason clearly about model architectures, training, evaluation, and tradeoffs.
  • Good research judgment about which ideas are worth testing and how to evaluate them.
  • Comfort working in an early-stage environment where the problems are hard and the path is still being defined.
  • Ability to work closely with domain experts outside machine learning.
  • Strong interest in applying machine learning to a problem in the physical world, not just at the software layer.
  • Substantial model development work, rather than only building products on top of model application programming interfaces.
Responsibilities
  • Design and run model experiments against difficult biological data.
  • Help define the research roadmap for how Tabula’s models should improve over time.
  • Work closely with the lab to shape what data gets generated and why.
  • Build better practices around experimentation, evaluation, and reproducibility.
  • Contribute to technical decisions around model design, training, and research direction.
  • Help a small team build an artificial intelligence company whose output is real therapies for real patients.

About the company

Tabula Bioscience uses machine learning to improve disease prediction and personalized medicine. Its core product aims to design programmable, strain-specific antimicrobials that target bacteria via bacteriophages, with R&D focused on phage therapy and gram-negative bacteria. The models leverage unlabeled genomic data from humans and other species, incorporate expert priors and epigenetic information, and use probabilistic programming to build mechanistic biological explanations. The goal is to narrow the gap between heritability and prediction to enable more effective, individualized treatments.

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 site says Tabula is treating real patients six months after launch.
  • 2026 hiring shows active Madison phage R&D on E. coli, Pseudomonas, and NGS.
  • Investors include George Church, Michael Seibel, Emmett Shear, Maven Ventures, and Version One.

What critics are saying

  • PitchBook still shows only a 2022 $2M seed, signaling thin capitalization.
  • Tabula’s 2026 job ads target temporary bench labor, not scaled manufacturing.
  • One failed clinical run in 2026-2027 ends Tabula’s financing and platform credibility.

What makes Tabula unique

  • Ammon Bartram and Michael Poon combine Triplebyte, Twitch, MIT, and polygenic-screening experience.
  • Tabula’s August 2026 site claims AI designs DNA for individual human infections.
  • Forward BIOLABS lists Tabula as a precision antimicrobial therapy startup.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Paid Vacation
  • 401(k) Company Match